Product information and disease descriptionProduct descriptionProduct information
Product comparison
18 evidence topics · 11 sources
Dosing, dosing frequency, and form: varegacestat in RINGSIDE Part B
Dosage form: varegacestat capsule formulations
Dosing, dosing frequency, and form: nirogacestat
Dosing, dosing frequency, and form: sorafenib in the phase 3 desmoid tumor trial
“In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400-mg tablet once daily) or matching placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose interruptions (of up to 28 days) and one dose reduction (to 200 mg once daily) were permitted and described in the trial protocol.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Half-life: BMS-986115 (varegacestat) in the phase 1 trial
Half-life: company claim for varegacestat relative to nirogacestat
Half-life: nirogacestat
Phase 3 efficacy: varegacestat in RINGSIDE Part B
Phase 3 efficacy: nirogacestat in DeFi
| DeFi outcome | OGSIVEO (N = 70) | Placebo (N = 72) |
|---|---|---|
| Patients with a progression-free survival event, n (%) | “12 (17)” | “37 (51)” |
| Median progression-free survival, months (95% CI) | “NR (NR, NR)” | “15.1 (8.4, NR)” |
| Objective response rate, n (%) | “29 (41)” | “6 (8)” |
| Objective response rate, 95% CI | “(29.8, 53.8)” | “(3.1, 17.3)” |
| Complete response, n (%) | “5 (7)” | “0” |
| Partial response, n (%) | “24 (34)” | “6 (8)” |
Phase 3 efficacy: sorafenib
“With a median follow-up of 27.2 months, the 2-year progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point was investigator-assessed progression-free survival; rates of objective response and adverse events were also evaluated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 3 safety: varegacestat in RINGSIDE Part B
Phase 3 safety: nirogacestat in DeFi
“Frequent adverse events with nirogacestat included diarrhea (in 84% of the patients), nausea (in 54%), fatigue (in 51%), hypophosphatemia (in 42%), and maculopapular rash (in 32%); 95% of adverse events were of grade 1 or 2. Among women of childbearing potential receiving nirogacestat, 27 of 36 (75%) had adverse events consistent with ovarian dysfunction, which resolved in 20 women (74%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 3 safety: sorafenib
“Among patients who received sorafenib, the most frequently reported adverse events were grade 1 or 2 events of rash (73%), fatigue (67%), hypertension (55%), and diarrhea (51%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“dose reductions due to toxic effects occurred in 31% (15 of 49) and 11% (4 of 35), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events led to a significantly higher rate of discontinuation of the trial regimen in the sorafenib group than in the placebo group (20% vs. no patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3 adverse events that were attributed to the trial regimen by the investigators occurred in 29% of patients in the sorafenib group and 14% of patients in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company cross-trial comparison of phase 3 objective response rates, with its disclaimer
| Phase 3 trial | Year shown | Regimen | Trial and size | Objective response rate, active | Objective response rate, placebo |
|---|---|---|---|---|---|
| Sorafenib | “2018” | “400mg Once Daily Oral” | “NCT02066181; N=87” | “ORR: 33%” | “ORR: 20%” |
| Nirogacestat | “2023” | “150 mg Twice-Daily Oral” | “DeFi; n=142” | “ORR: 41%” | “ORR: 8%” |
| Varegacestat | “2025” | “1.2mg Once-Daily Oral” | “RINGSIDE; N=156” | “ORR: 56%” | “ORR: 9%” |
Company and investigator comparative statements
Wholesale acquisition cost of nirogacestat, January 2026
| Product | NDC | Dosage form and strength | Wholesale acquisition cost |
|---|---|---|---|
| OGSIVEO 100 mg | “82448-0100-14” | “Oral Tablet 100 MG” | “$7,746.58” |
| OGSIVEO 150 mg | “82448-0150-14” | “Oral Tablet 150 MG” | “$7,746.58” |